Advertisement

Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant® implant users

      Abstract

      A double-blind, placebo-controlled, randomized trial, was carried out in 120 Norplant® users to evaluate the effect of mifepristone, 100 mg/day administered for 2 consecutive days every 30 days, on the vaginal bleeding pattern. Treatment was given from months 2–7 of implant use. Volunteers recorded bleeding and spotting days, during treatment and for the ensuing 6-month period. During treatment, women on mifepristone recorded the same frequency of bleeding/spotting episodes but significantly less prolonged bleeding episodes than placebo controls (mean ± SD: 11 ± 3 vs. 22 ± 23 days) and their total number of bleeding days was 35% lower than in the placebo group. After the end of mifepristone use, bleeding patterns were similar in both groups. One pregnancy occurred in the mifepristone-treated group, in month 6 of treatment, the outcome was a healthy male baby. We conclude that intermittent administration of mifepristone can offer a clinically significant improvement of the vaginal bleeding pattern in Norplant users.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Faundes A.
        • Sivin I.
        • Stern J.
        Long-acting contraceptive implants.
        Contraception. 1978; 18: 355-365
        • Odlind V.
        • Fraser I.S.
        Contraception and menstrual bleeding disturbances: a clinical overview.
        in: D'Arcangues C. Fraser I.S. Newton J.R. Odlind V. Contraception and mechanisms of endometrial bleeding. Cambridge University Press, Cambridge (UK)1990: 5-32
        • Fraser I.S.
        • Tiitinen A.
        • Affandi B.
        • et al.
        Norplant consensus statement and background review.
        Contraception. 1998; 57: 1-9
        • Sivin I.
        • Campodonico I.
        • Kiriwat O.
        • et al.
        The performance of levonorgestrel rod and Norplant® contraceptive implants.
        Hum Reprod. 1998; 13: 3371-3378
        • Zheng S.-R.
        • Zheng H.-M.
        • Qian S.-Z.
        • et al.
        A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant.
        Contraception. 1999; 60: 1-8
        • International Collaborative Post-Marketing Surveillance of Norplant
        Post-marketing surveillance of Norplant® contraceptive implants.
        Contraception. 2001; 63: 167-186
        • Fraser I.S.
        • Hickey M.
        • Song J.Y.
        A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception.
        Hum Reprod. 1996; 11: 165-178
        • Hickey M.
        • Fraser I.S.
        A functional model for progestogen-induced breakthrough bleeding.
        Hum Reprod. 2000; 15: 1-6
        • Smith S.K.
        Steroids and endometrial breakthrough bleeding.
        Hum Reprod. 2000; 15: 197-202
        • Hickey M.
        • d'Arcangues C.
        Vaginal bleeding disturbances and implantable contraceptives.
        Contraception. 2002; 65: 75-84
        • Fraser I.S.
        A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives.
        Contraception. 1983; 28: 85-97
        • Nutley T.
        • Dunson T.R.
        Treatment of bleeding problems associated with progestin-only contraceptives.
        Adv Contracep. 1997; 13: 419-428
        • Díaz S.
        • Croxatto H.B.
        • Pavez M.
        • et al.
        Clinical assessment of treatments for prolonged bleeding in users of Norplant® implants.
        Contraception. 1990; 42: 97-109
        • Alvarez-Sánchez F.
        • Brache V.
        • Thevenin F.
        • et al.
        Hormonal treatment for bleeding irregularities in Norplant implant users.
        Am J Obstet Gynecol. 1996; 174: 919-922
        • Witjaksono J.
        • Lau T.M.
        • Affandi B.
        • Rogers P.A.W.
        Oestrogen treatment for increased bleeding in Norplant users.
        Hum Reprod. 1996; 11: 109-114
        • Boonkaasemsanti W.
        • Reinprayoon D.
        • Pruksananonda K.
        • et al.
        The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
        Hum Reprod. 1996; 11: 115-123
        • Subakir S.B.
        • Madjid O.A.
        • Sabariah S.
        • Affandi B.
        Oxidative stress, vitamin E and progestin breakthrough bleeding.
        Hum Reprod. 2000; 15: 18-23
        • D'Arcangues C.
        Management of vaginal bleeding irregularities induced by progestin-only contraceptives.
        Hum Reprod. 2000; 15: 24-29
        • World Health Organization
        Reproductive Health and Research Family and Community Health. Selected Practice Recommendations for Contraceptive Use.
        World Health Organization, Geneva2002
        • Shoupe D.
        • Mishell Jr, D.R.
        • Lähteenmäki P.
        • et al.
        Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase.
        Am J Obstet Gynecol. 1987; 157: 1415-1420
        • Croxatto H.B.
        • Salvatierra A.M.
        • Romero C.
        • Spitz I.
        Late luteal phase administration of RU 486 for three consecutive cycles does not disrupt bleeding patterns or ovulation.
        J Clin Endocrinol Metab. 1987; 65: 1272-1277
        • Croxatto H.B.
        • Salvatierra A.M.
        • Croxatto H.D.
        • Spitz I.
        Variable effect of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
        Clin Endocrinol (Oxf). 1989; 31: 15-23
        • Schaison G.
        • George M.
        • Lestrat N.
        • Reinberg A.
        • Baulieu E.E.
        Effects of the antiprogesterone steroid RU486 during midluteal phase in normal women.
        J Clin Endocrinol Metab. 1985; 61: 484-489
        • Belsey E.
        • Farley T.
        The analysis of menstrual bleeding patterns.
        Contraception. 1988; 38: 129-156
        • Cheng L.
        • Zhu H.
        • Wang A.
        • Ren F.
        • Chen J.
        • Glasier A.
        Once-a-month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.
        Hum Reprod. 2000; 15: 1969-1972
        • Gemzell Danielsson K.
        • van Heusden A.M.
        • Killick S.R.
        • et al.
        Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.
        Hum Reprod. 2002; 17: 2588-2593
        • Glasier A.
        Implantable contraceptives for women.
        Contraception. 2002; 65: 29-37
        • Brache V.
        • Faúndes A.
        • Johansson E.
        • Alvarez F.
        Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants.
        Contraception. 1985; 31: 261-273
        • Croxatto H.B.
        • Diaz S.
        • Salvatierra A.M.
        Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro.
        Contraception. 1987; 36: 193-201
        • Dunson T.R.
        • Blumenthal P.D.
        • Alvarez F.
        • et al.
        Timing of onset of contraceptive effectiveness in Norplan implant users. Changes in cervical mucus.
        Fertil Steril. 1988; 69: 258-266
        • Croxatto H.B.
        Mechanisms that explain the contraceptive action of progestin implants for women.
        Contraception. 2002; 65: 21-27
        • Croxatto H.B.
        • Salvatierra A.M.
        Cyclic use of antiprogestagens for fertility control.
        in: Runnebaum B. Rabe T. Kiesel L. Female contraception and male fertility regulation. Parthenon, New York1991: 245-252
        • Fotherby K.
        Potency and pharmacokinetic of gestogens.
        Contraception. 1990; 41: 533-550
        • Lähteenmäki P.
        • Heikinheimo O.
        • Croxatto H.B.
        • et al.
        Pharmacokinetics and metabolism of RU486.
        J Steroid Biochem. 1987; 27: 859-863
        • Gravanis A.
        • Schiason G.
        • George M.
        • et al.
        Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women.
        J Clin Endocrinol Metab. 1985; 60: 156-163
        • Croxatto H.B.
        Norplant.
        Ann Med. 1993; 25: 155-160
        • Kuhnz W.
        • Fritzemeier K.H.
        • Hegele-Hartung C.
        • Krattenmacher R.
        Comparative progestational activity of norgestimate, levonorgestrel-oxime and levonorgestrel in the rat and binding of these compounds to the progesterone receptor.
        Contraception. 1995; 51: 131-139
        • van Heusden A.M.
        • Killick S.R.
        • Coelingh Bennink H.J.T.
        • Fauser B.C.J.M.
        Single monthly administration of the anti-progestagen ORG 31710 in users of the 75 ug desogestrel progestagen-only pill.
        Hum Reprod. 2000; 15: 629-636